- Details
- Pedro Barata and Martin Voss discuss a clinical trial investigating subsequent therapies for advanced Renal Cell Carcinoma (aRCC) patients. Dr. Voss provides an in-depth explanation of a new endpoint, Progression-Free Survival 2 (PFS 2), which measures time from randomization to disease progression on the next line of therapy. He emphasizes its significance in kidney cancer research, noting that i...
|
- Details
- Pedro Barata converses with Neil Shah about his research on clinical outcomes for patients with advanced RCC. They focus on two of Dr. Shah's studies: 'Real-World Clinical Outcomes of Patients with Metastatic Renal Cell Carcinoma Receiving Pembrolizumab + Axitinib vs Ipilimumab + Nivolumab’, and ‘Real-World Assessment of Changing Treatment Patterns and Sequence for Patients with Metastatic RCC in...
|
- Details
- Pedro Barata hosts Hesham Yasin to discuss his project on the implementation of artificial intelligence (AI) to analyze patient data. Dr. Yasin and his team developed a machine learning model to assess over 2,000 patients with advanced renal cell carcinoma for their risk of cardiotoxicity, in relation to their VEGF therapy. The AI, trained to recognize specific risk factors, performed at an impres...
|
- Details
- Pedro Barata and Michael Atkins discuss the significant findings of the TIVO-3 trial. The trial compared the effects of tivozanib, a selective tyrosine kinase inhibitor (TKI), and sorafenib, an older TKI in patients with relapsed or refractory advanced RCC. Dr. Atkins highlights the improved progression-free survival rates and better tolerability observed with tivozanib despite initial concerns ab...
|
- Details
- Camillo Porta provides a comprehensive overview of the CLEAR trial, an impactful research investigation into lenvatinib/pembrolizumab (lenv/pembro) as a first-line treatment for patients with advanced clear cell kidney cancer. The study showed significant survival benefits in favor of the combination treatment compared to sunitinib, a previous standard treatment for the disease. The conversation a...
|
- Details
- Pedro Barata discusses the work of his team on tivozanib, a selective androgenic therapy approved for patients with advanced renal cell carcinoma (RCC). Their research focused on non-clear cell RCC, a less common subset of RCC. The team re-examined a Phase II trial conducted several years ago, using tivozanib in a discontinuation trial. The trial enrolled over 270 patients, of whom over 45 had non...
|
- Details
- Pedro Barata discusses the TIVO-3 trial with Kathryn Beckermann. The trial assessed Tivozanib, a novel tyrosine kinase inhibitor (TKI), used in the treatment of refractory clear cell RCC patients. They explain that the primary endpoint of the trial was progression-free survival (PFS), but they also delve into the complexities of considering overall survival (OS) in global trials. This leads to a d...
|
- Details
- Pedro Barata interviews Mehmet Asim Bilen to discuss his recent research on neoadjuvant cabozantinib treatment in patients with renal cell carcinoma. Dr. Bilen elaborates on the study's design and rationale, stating that neoadjuvant therapy could potentially facilitate partial nephrectomy and understand the biology of the disease. The phase II study included 17 patients and reported a 30% response...
|
- Details
- Alicia Morgans hosts a discussion with William Hall and Rana McKay to discuss SAMURAI, the first cooperative group study that randomizes patients with kidney cancer between radiation and no radiation. Dr. Hall points out how radiation therapy has evolved over the past 15 years, offering high doses with millimeter accuracy that precisely targets malignancy while avoiding normal tissue. This evoluti...
|
- Details
- Pedro Barata hosts Kelly Fitzgerald known for her exceptional research in kidney cancer. They discuss Dr. Fitzgerald's paper in European Neurology, focusing on the progression-free survival of second line therapy for advanced clear cell in patients treated with Immuno-Oncology (IO) based approaches. Dr. Fitzgerald explains how they aimed to understand the therapeutic sequencing between ipilimumab...
|
